Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) [Phase 3]

View source ↗

Summary

Phase 3 CARES trial evaluating CAEL-101 for Mayo Stage IIIb AL amyloidosis is ongoing and currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Drugs mentioned

• CAEL-101 (birtamimab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: AL Amyloidosis | Phase 3 | Status: ACTIVE_NOT_RECRUITING